{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-017852","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.859138+00:00","generated_at":"2026-06-26T00:36:26.250064+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adaptive Biotechnologies Q1 revenue $38.6M (+0.5% YoY); net loss widens to $62.8M","bullets":["clonoSEQ test volume grew 45% YoY and 12% QoQ; MRD regulatory milestone revenue of $3.0M from partner drug approval.","T-Detect Lyme sensitivity 54% vs SOC 30% at 99% specificity; launch planned for 2022 Lyme season.","Entered T-MAP collaboration with Janssen for RSV vaccine program; appointed Tycho Peterson as CFO.","Revenue guidance for FY2022 reaffirmed at $185-195M; cash and securities $500.7M as of March 31."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-017852","json":"https://secwatch.observer/filing/0001564590-22-017852.json","markdown":"https://secwatch.observer/filing/0001564590-22-017852.md","text":"https://secwatch.observer/filing/0001564590-22-017852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000156459022017852/0001564590-22-017852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000156459022017852/adpt-8k_20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:36:26.250064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}